These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 18296419)

  • 1. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.
    Crump M; Coiffier B; Jacobsen ED; Sun L; Ricker JL; Xie H; Frankel SR; Randolph SS; Cheson BD
    Ann Oncol; 2008 May; 19(5):964-9. PubMed ID: 18296419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
    Duvic M; Talpur R; Ni X; Zhang C; Hazarika P; Kelly C; Chiao JH; Reilly JF; Ricker JL; Richon VM; Frankel SR
    Blood; 2007 Jan; 109(1):31-9. PubMed ID: 16960145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
    Olsen EA; Kim YH; Kuzel TM; Pacheco TR; Foss FM; Parker S; Frankel SR; Chen C; Ricker JL; Arduino JM; Duvic M
    J Clin Oncol; 2007 Jul; 25(21):3109-15. PubMed ID: 17577020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
    Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
    Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
    Garcia-Manero G; Yang H; Bueso-Ramos C; Ferrajoli A; Cortes J; Wierda WG; Faderl S; Koller C; Morris G; Rosner G; Loboda A; Fantin VR; Randolph SS; Hardwick JS; Reilly JF; Chen C; Ricker JL; Secrist JP; Richon VM; Frankel SR; Kantarjian HM
    Blood; 2008 Feb; 111(3):1060-6. PubMed ID: 17962510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
    Vansteenkiste J; Van Cutsem E; Dumez H; Chen C; Ricker JL; Randolph SS; Schöffski P
    Invest New Drugs; 2008 Oct; 26(5):483-8. PubMed ID: 18425418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
    Blumenschein GR; Kies MS; Papadimitrakopoulou VA; Lu C; Kumar AJ; Ricker JL; Chiao JH; Chen C; Frankel SR
    Invest New Drugs; 2008 Feb; 26(1):81-7. PubMed ID: 17960324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
    Kirschbaum M; Frankel P; Popplewell L; Zain J; Delioukina M; Pullarkat V; Matsuoka D; Pulone B; Rotter AJ; Espinoza-Delgado I; Nademanee A; Forman SJ; Gandara D; Newman E
    J Clin Oncol; 2011 Mar; 29(9):1198-203. PubMed ID: 21300924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
    Eyre TA; Hildyard C; Hamblin A; Ali AS; Houlton A; Hopkins L; Royston D; Linton KM; Pettitt A; Rule S; Cwynarski K; Barrington SF; Warbey V; Wrench D; Barrans S; Hirst CS; Panchal A; Roudier MP; Harrington EA; Davies A; Collins GP
    Hematol Oncol; 2019 Oct; 37(4):352-359. PubMed ID: 31385336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.
    Wada H; Tsuboi R; Kato Y; Sugaya M; Tobinai K; Hamada T; Shimamoto T; Noguchi K; Iwatsuki K
    J Dermatol; 2012 Oct; 39(10):823-8. PubMed ID: 22506596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
    Hopfinger G; Nösslinger T; Lang A; Linkesch W; Melchardt T; Weiss L; Egle A; Greil R
    Ann Hematol; 2014 Mar; 93(3):459-62. PubMed ID: 24441915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.
    Straus DJ; Hamlin PA; Matasar MJ; Lia Palomba M; Drullinsky PR; Zelenetz AD; Gerecitano JF; Noy A; Hamilton AM; Elstrom R; Wegner B; Wortman K; Cella D
    Br J Haematol; 2015 Mar; 168(5):663-70. PubMed ID: 25316653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
    Yazbeck V; Shafer D; Perkins EB; Coppola D; Sokol L; Richards KL; Shea T; Ruan J; Parekh S; Strair R; Flowers C; Morgan D; Kmieciak M; Bose P; Kimball A; Badros AZ; Baz R; Lin HY; Zhao X; Reich RR; Tombes MB; Shrader E; Sankala H; Roberts JD; Sullivan D; Grant S; Holkova B
    Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):569-575.e1. PubMed ID: 30122201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.
    Watanabe T; Kato H; Kobayashi Y; Yamasaki S; Morita-Hoshi Y; Yokoyama H; Morishima Y; Ricker JL; Otsuki T; Miyagi-Maesima A; Matsuno Y; Tobinai K
    Cancer Sci; 2010 Jan; 101(1):196-200. PubMed ID: 19817748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
    Duvic M; Olsen EA; Breneman D; Pacheco TR; Parker S; Vonderheid EC; Abuav R; Ricker JL; Rizvi S; Chen C; Boileau K; Gunchenko A; Sanz-Rodriguez C; Geskin LJ
    Clin Lymphoma Myeloma; 2009 Dec; 9(6):412-6. PubMed ID: 19951879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.
    Pera B; Tang T; Marullo R; Yang SN; Ahn H; Patel J; Elstrom R; Ruan J; Furman R; Leonard J; Cerchietti L; Martin P
    Clin Epigenetics; 2016; 8():79. PubMed ID: 27453763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium.
    Bradley D; Rathkopf D; Dunn R; Stadler WM; Liu G; Smith DC; Pili R; Zwiebel J; Scher H; Hussain M
    Cancer; 2009 Dec; 115(23):5541-9. PubMed ID: 19711464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.
    Richardson P; Mitsiades C; Colson K; Reilly E; McBride L; Chiao J; Sun L; Ricker J; Rizvi S; Oerth C; Atkins B; Fearen I; Anderson K; Siegel D
    Leuk Lymphoma; 2008 Mar; 49(3):502-7. PubMed ID: 18297527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.